CIRM Funded Clinical Trials
A phase 1/2 study to evaluate a bispecific CD19/CD20-directed CAR T cell, in refractory lupus nephritis and systemic lupus erythematosus
Disease Area:
Immune Disease
Trial Sponsor:
ImmPACT-Bio, Inc.
Trial Stage:
Phase 1/2
Trial Status:
Launching
Targeted Enrollment:
N/A
